Holen Sie sich die Stockscreener-App
7.18
9.12%
0.60
Handel nachbörslich:
7.13
-0.05
-0.70%
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - Stock Traders Daily
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Verastem (VSTM) Q2 2026 Earnings Call Transcript - aol.com
Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem Inc (VSTM) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
VSTM Maintains by Mizuho -- Price Target Lowered to $13.00 - GuruFocus
Mizuho lowers Verastem stock price target on valuation to $13 - Investing.com
Mizuho lowers Verastem stock price target on valuation to $13 By Investing.com - Investing.com UK
Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating - Yahoo Finance
Verastem (VSTM) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Q2 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Weekly Recap: Q2 2026 revenue, cash, losses and RAMP Phase 3 readout - TradingView
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18 - Moomoo
Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure - Sahm
Verastem Inc (VSTM) Stock News Today - TradingKey
Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Verastem Q2 Earnings Call Highlights - MarketBeat
VSTM Maintained by Guggenheim -- Price Target Lowered to $12.00 - GuruFocus
Verastem Oncology (VSTM) Posts Solid Q2 2026; Market Pricing Ref - GuruFocus
State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock - Stock Titan
Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside - TradingView
VerastemEnters Amendment No. 3 To Note Purchase Agreement On August 6, 2026SEC Filing - TradingView
Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingView
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong R - GuruFocus
How Did Verastem Inc (VSTM) Perform in Q2 2026? Revenue of $40.1 - GuruFocus
Earnings call transcript: Verastem beats Q2 2026 estimates, shares jump after hours - Investing.com
Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verastem, Inc. 2026: Revenue $40.08M, EPS ($0.35) — 10-Q Summary - TradingView
VERASTEM ($VSTM) Releases Q2 2026 Earnings - Moomoo
Verastem: Q2 Earnings Snapshot - Barchart.com
Verastem (Nasdaq: VSTM) lifts Q2 2026 revenue to $40M, discloses going‑concern risk - Stock Titan
Verastem Q2 revenue jumps on new product sales and milestone - TradingView
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Verastem Inc (VSTM) President and CEO Dan Paterson Sells 1,302 S - GuruFocus
BlackRock, Inc. Trims Verastem Inc (VSTM) Stake in Recent 13DG F - GuruFocus
Verastem, Inc. (VSTM) CEO sells 1,302 shares to cover RSU taxes - Stock Titan
VSTM|Verastem Inc|Price:5.695|Chg%:-0.105 - TradingKey
Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $14 to $18 - Moomoo
Earnings Preview: Verastem to Report Financial Results Post-market on August 06 - Moomoo
Vanguard Capital Management (VSTM) discloses 4.42M Verastem shares in 13G filing - Stock Titan
Verastem, Inc. Revenue Breakdown – NASDAQ:VSTM - TradingView
Verastem (VSTM) to Post Quarterly Earnings on Thursday - MarketBeat
Verastem Oncology (NASDAQ:VSTM) Draws Attention After Fresh Market Update - Kalkine Media
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Yahoo Finance
Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verastem Inc (VSTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Verastem Inc (VSTM) Balance Sheet - TradingKey
Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Verastem Inc (VSTM) Income Statement - TradingKey
VSTM|Verastem Inc|Price:6.085|Chg%:+0.035 - TradingKey
Verastem Inc (VSTM) Cash Flow - TradingKey
Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold" - marketbeat.com
Verastem, Inc. Revenue Breakdown – HAM:2VSA - TradingView
VSTM|Verastem Inc|Price:6.050|Chg%:-0.130 - TradingKey
Verastem Inc. (VSTM) holder outlines potential sale of 31,924 common shares - Stock Titan
Verastem Oncology to report Q2 2026 results on Aug 6 - scanx.trade
Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Moomoo
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):